Merz’s Xeomin gains FDA approval as first neurotoxin treatment for sialorrhea

FirstWord 2018/07/04

Merz announced that the FDA approved Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea in adults, making the product the first neurotoxin authorised in this indication in the US. Kevin O’Brien, US head of neurosciences at Merz, said “until now, there has not been an FDA approved treatment for this debilitating condition,” which is a common symptom among patients who suffer from neurological disorders including Parkinson’s disease, amyotrophic lateral sclerosis, cerebral palsy or who have experienced a stroke.

The FDA accepted the filing for Xeomin in sialorrhea in March, assigning the application priority review a target action date in the fourth quarter. The submission was based on data from a Phase III study in 184 patients with sialorrhea, which met both its co-primary endpoints. Results showed a significant improvement in change in unstimulated salivary flow rate and Global Impression of Change Scale, both at week four as compared to baseline pre-injection for subjects administered Xeomin versus placebo.

Merz noted that this is the fourth neurological indication for Xeomin, following previous FDA approvals for the treatment of cervical dystonia, blepharospasm and upper limb spasticity.

「ポチッ」して頂けると励みになります♡

仲間募集中

業務拡大につき、看護師、理学療法士、作業療法士、事務職+保育士・歯科衛生士・栄養士・管理栄養士さんを募集中。
週1回1時間から働ける柔軟で明るい職場で、子育てママや社会人学生も在籍。
すぐに考えていないけれど、少しでも御関心があれば、とりあえず雑談させて下さいませ。

コメントを残す